INCHEON, Korea, November 11, 2025--(BUSINESS WIRE)--Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of ...
Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform INCHEON, ...
Samsung Epis Holdings announced Tuesday that it has established a new subsidiary, Epis NexLab, to seek new growth engines by developing biotechnology platforms. The launch of Epis NexLab, whose name ...
Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO. Byooviz is indicated for the treatment of ...
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research ...
Samsung Epis Holdings Co., Ltd. announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexLab will ...
The MarketWatch News Department was not involved in the creation of this content. -- Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting ...
Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings, announced a research collaboration and license agreement with G2GBIO, a company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results